## Mostafa Jarahian

## List of Publications by Citations

Source: https://exaly.com/author-pdf/9914327/mostafa-jarahian-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29 1,175 13 31 h-index g-index citations papers 1,846 7.8 4.17 31 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
29	Brain tumour cells interconnect to a functional and resistant network. <i>Nature</i> , <b>2015</b> , 528, 93-8	50.4	496
28	Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. <i>Journal of Virology</i> , <b>2009</b> , 83, 8108-21	6.6	129
27	Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. <i>PLoS ONE</i> , <b>2007</b> , 2, e1339	3.7	79
26	Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. <i>PLoS Pathogens</i> , <b>2011</b> , 7, e1002195	7.6	77
25	CAR T cells in solid tumors: challenges and opportunities. <i>Stem Cell Research and Therapy</i> , <b>2021</b> , 12, 81	8.3	72
24	Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool. <i>Glycobiology</i> , <b>2008</b> , 18, 28-41	5.8	51
23	Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. <i>International Journal of Cancer</i> , <b>2007</b> , 120, 2625-34	7.5	39
22	Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders. <i>Stem Cell Research and Therapy</i> , <b>2021</b> , 12, 192	8.3	35
21	Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol. <i>Frontiers in Bioengineering and Biotechnology</i> , <b>2021</b> , 9, 705886	5.8	35
20	A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine. <i>Journal of Translational Medicine</i> , <b>2021</b> , 19, 302	8.5	24
19	Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities. <i>Stem Cell Research and Therapy</i> , <b>2021</b> , 12, 297	8.3	23
18	CAR-NK Cell: A New Paradigm in Tumor Immunotherapy. Frontiers in Oncology, 2021, 11, 673276	5.3	18
17	CAR-NK cell in cancer immunotherapy; A promising frontier. <i>Cancer Science</i> , <b>2021</b> , 112, 3427-3436	6.9	17
16	The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction. <i>Cancer Letters</i> , <b>2020</b> , 474, 82-93	9.9	12
15	Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. <i>Stem Cell Research and Therapy</i> , <b>2021</b> , 12, 465	8.3	12
14	Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib. <i>Lung Cancer</i> , <b>2014</b> , 86, 151-7	5.9	10
13	Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. <i>Stem Cell Research and Therapy</i> , <b>2021</b> , 12, 200	8.3	9

## LIST OF PUBLICATIONS

12	Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism. Stem Cell Research and Therapy, <b>2021</b> , 12, 217	8.3	7	
11	Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 699746	8.4	6	
10	Cloning and Embryo Splitting in Mammalians: Brief History, Methods, and Achievements. <i>Stem Cells International</i> , <b>2021</b> , 2021, 2347506	5	4	
9	A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 681984	8.4	4	
8	Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 721174	4.9	4	
7	The lethal internal face of the coronaviruses: Kidney tropism of the SARS, MERS, and COVID19 viruses. <i>IUBMB Life</i> , <b>2021</b> , 73, 1005-1015	4.7	3	
6	Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 686453	5.7	3	
5	Re-Expression of Poly/Oligo-Sialylated Adhesion Molecules on the Surface of Tumor Cells Disrupts Their Interaction with Immune-Effector Cells and Contributes to Pathophysiological Immune Escape. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2	
4	Up-regulation of KISS1 as a novel target of Let-7i in melanoma serves as a potential suppressor of migration and proliferation in vitro. <i>Journal of Cellular and Molecular Medicine</i> , <b>2021</b> , 25, 6864-6873	5.6	2	
3	Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein. <i>Journal of Innate Immunity</i> , <b>2021</b> , 1-13	6.9	1	
2	Expression and Purification of a Bispecific Antibody against CD16 and Hemagglutinin Neuraminidase (HN) in for Cancer Immunotherapy. <i>Reports of Biochemistry and Molecular Biology</i> , <b>2020</b> , 9, 50-57	1.3	О	
1	Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy.  International Immunopharmacology, <b>2021</b> , 96, 107762	5.8	О	